Senseonics Earnings Call Highlights Rapid Growth Push

Senseonics Holdings Inc. ((SENS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Senseonics Holdings Inc. struck an upbeat tone on its latest earnings call, spotlighting rapid top-line growth, improving margins, and fresh capital to fund expansion. Management acknowledged sharply higher operating expenses and losses but argued the company is building a durable growth platform, with execution through the rest of 2026 framed as the key investor watchpoint.

Surging Q1 Revenue Underscores Growth Momentum

Net revenue jumped to $11.7 million in Q1 2026, up 85% from $6.3 million a year earlier, reflecting strong adoption of the Eversense 365 sensor. U.S. sales contributed $9.3 million, while international markets delivered $2.4 million, showing that growth is broad-based even as the company continues to transition its overseas operations.

Margin Expansion Supports Profitability Path

Gross margin reached 58% in Q1, or roughly 54% excluding a one-time $0.5 million benefit to cost of goods. Gross profit climbed to $6.9 million, up $5.4 million year-over-year, and management raised full-year 2026 gross margin guidance to 55%–58%, reinforcing confidence in scaling the model efficiently.

Full-Year Revenue Outlook Raised Again

Senseonics lifted its 2026 global net revenue guidance to a range of $60 million to $64 million, up from $58 million to $62 million previously. The new outlook implies robust year-over-year growth of about 70% to 82%, signaling management’s conviction that early 2026 momentum is sustainable.

U.S. Commercial Integration Fuels Execution

The company completed the transition of its U.S. commercial operations from its former partner on January 1, bringing sales and marketing fully in-house. Management credited the seamless handoff with boosting Q1 performance and margin expansion, citing tighter alignment across pricing, promotion, and field execution.

Direct-to-Consumer Engine Accelerates Growth

Senseonics reported that direct-to-consumer new patient shipments nearly doubled versus Q1 2025 and made up about 60% of all new patient starts. The company expects to hold DTC spend at roughly $13 million in 2026 while benefiting from better cost per lead and improved conversion, pointing to a more efficient acquisition engine.

Eon Care Expands Insertion Capacity Nationwide

Eon Care, the company’s insertion services arm, now has over 70 nurses and handles more than one-third of all Eversense insertions. With a presence in 34 states and a target of 100 nurses by year-end, management sees Eon Care as a key tool to reduce geographic access barriers and support scalable national growth.

Pipeline Advances With Gemini and Freedom

On the innovation front, Senseonics reiterated that Gemini, its one-year sensor with a battery, remains on schedule for the first half of 2027. Freedom, a one-year sensor with integrated Bluetooth, is slated to enter first-in-human trials in the second half of 2026, alongside app upgrades and planned AI features later this year to enhance user experience.

Balance Sheet Reinforced by Debt and Equity Raises

To fund its growth agenda, the company expanded its Hercules credit facility from $100 million to $140 million and drew an additional $20 million, bringing total debt outstanding to about $55 million. It also completed a public equity raise totaling $92 million in gross proceeds, ending March with $64.6 million in cash, restricted cash, and equivalents.

Partnerships and Clinical Data Build Ecosystem

Senseonics launched its first automated insulin delivery partnership, integrating the Eversense 365 sensor with Sequel Med Tech’s twiist pump. Early uptake has been encouraging, and positive clinical data shared at a major diabetes meeting, with more real-world results set for an upcoming conference, is helping validate the technology with clinicians and patients.

Retention and Reorders Strengthen Recurring Base

Patient reorders tracked ahead of internal targets in Q1, bolstering visibility into recurring revenue. Management highlighted historical retention of about 75% from first to second sensor, roughly 85% from second to third, and over 90% thereafter, and said early data for the one-year sensor suggest even better-than-modeled retention.

Heavy Operating Spend Drives Wider Net Loss

The aggressive commercial build-out came at a cost, with Q1 2026 net loss widening to $32.3 million, or $0.71 per share, versus $14.3 million, or $0.40, a year ago. SG&A expenses surged to $30.2 million on integration, transition services, and marketing, while R&D rose to $8.6 million as the pipeline moves toward pivotal trials.

Elevated Cash Burn and Leverage Profile

Management guided to 2026 operating expenses of $150 million to $160 million and cash utilization of $110 million to $120 million, reflecting the step-up in commercial and clinical investment. Debt and accrued interest were $35.2 million at quarter-end, with total debt of $55 million after the recent draw, underscoring higher leverage in support of growth.

European Transition Still a Work in Progress

While the U.S. transition was described as seamless, Senseonics is still in the midst of shifting European operations in markets such as Germany, Italy, Spain, and Sweden. Hiring, business system transfers, and tender migrations are expected to wrap up this quarter, but management cautioned there could be short-term operational lag outside the U.S.

Seasonality and Back-Half Weighted Sales

The company reminded investors that its business is seasonal, with roughly 40% of revenue expected in the first half and 60% in the second half of the year. Historical concentration in the back half, influenced by insurance dynamics and patient assistance usage, could make near-term quarterly trends choppy even as annual growth remains strong.

Competitive Landscape Demands Constant Differentiation

Rivals are advancing their own sensor technologies and pricing strategies, forcing Senseonics to keep sharpening its edge through longer-wear sensors and integration with automated insulin delivery systems. Management emphasized that maintaining DTC efficiency, driving physician adoption, and delivering clear product differentiation will be crucial to defending and growing share.

Guidance and Outlook Emphasize Growth With Risk

For 2026, Senseonics now expects global net revenue of $60 million to $64 million, gross margins of 55% to 58%, and a seasonal split of about 40% of sales in the first half and 60% in the second. The company plans roughly $13 million of DTC spend, expects reorders to be about 40% of U.S. volume, anticipates bundled-pay to reach about 60% of shipments, and aims to double its U.S. patient base this year.

Senseonics’ latest call painted a picture of a company in acceleration mode, pairing rapid revenue growth and improving unit economics with heavier spending and rising leverage. Investors will be watching whether management can convert its stronger commercial footing, pipeline progress, and fresh capital into durable share gains while navigating execution risks and a competitive diabetes technology market.